Abstract:Objective: To evaluate the value of p16INK4a detected by p16INK4a immunostaining as a new generation of cervical cytology for primary screening and secondary screening in population-based cervical cancer screening, and in improving cytological diagnosis. Methods: Between 2016 and 2018, 5 747 non-pregnant women aged 25-65 years with sexual history were recruited and underwent cervical cancer screening via high-risk (HR)-HPV/liquid-based cytological test (LCT) test in Shenzhen and surrounding areas. All slides were immuno-stained using p16INK4a technology, among them, 902 cases were offered p16INK4a detection during primary screening, and the remaining 4 845 cases were called-back by the virtue of abnormal HR-HPV and LCT results for p16INK4a staining. Participants with complete LCT examination, HR-HPV test, p16INK4a staining and histopathological examination results were included in this study. The performance of p16INK4a in primary and secondary screening, and in assisting cytology to detect high grade squamous intraepithelial lesion [HSIL, including cervical intraepithelial neoplasia (CIN) Ⅱ or Ⅲ] or worse [HSIL (CIN Ⅱ)+ or HSIL (CIN Ⅲ)+] were analyzed. Results: (1) One-thousand and ninety-seven cases with complete data of p16INK4a and histology were included. Pathological diagnosis: 995 cases of normal cervix, 37 cases of low grade squamous intraepithelial lesion (LSIL), 64 cases of HSIL and one case of cervical cancer were found. Among them, 65 cases of HSIL (CIN Ⅱ)+ and 34 cases of HSIL (CIN Ⅲ)+ were detected. The positive rate of p16INK4a in HSIL (CIN Ⅱ)+ was higher than that in CINⅠ or normal pathology (89.2% vs 10.2%; P<0.01). (2) p16INK4a as primary screening for HSIL (CIN Ⅱ)+ or HSIL (CIN Ⅲ)+ was equally sensitive to primary HR-HPV screening (89.2% vs 95.4%, 94.1% vs 94.1%; P>0.05), but more specific than HR-HPV screening (89.8% vs 82.5%, 87.7% vs 80.2%; P<0.05). p16INK4a was equally sensitive and similarly specific to cytology (≥LSIL; P>0.05). (3) The specificity of LCT adjunctive p16INK4a for detecting HSIL (CIN Ⅱ)+ or HSIL (CIN Ⅲ)+ were higher than that of LCT alone or adjunctive HR-HPV (P<0.01), while the sensitivity were similar (P>0.05). (4) p16INK4a staining as secondary screening: p16INK4a was significantly more specific (94.1% vs 89.7%, 91.9% vs 87.4%; P<0.01) and comparably sensitive (84.6% vs 90.8%, 88.2% vs 91.2%; P>0.05) to cytology for triaging primary HR-HPV screening. HPV 16/18 to colposcopy and triage other HR-HPV with p16INK4a was equally sensitive (88.2% vs 94.1%; P=0.500) and more specific (88.3% vs 83.0%; P<0.01) than HPV 16/18 to colposcopy and triage other HR-HPV with LCT≥ atypical squamous cells of undetermined significance (ASCUS), and the referral rate decreased (14.0% vs 19.4%; P=0.005). Conclusions: For primary screening, p16INK4a is equally specific to cytology and equally sensitive to HR-HPV screening. p16INK4a alone could be an efficient triage after primary HR-HPV screening. In addition, p16INK4a immunostaining could be used as an ancillary tool to cervical cytological diagnosis, and improves its accuracy in cervical cancer screening.

P16ink4a Immunohistochemical Staining and Predictive Value for Progression of Cervical Intraepithelial Neoplasia Grade 1: a Prospective Study in China.

The value of p16 INK4a immunostaining for high-grade squamous intraepithelial lesions in human papillomavirus-negative patients

[Evaluation of P16(INK4α) Expression in Thinprep Cervical Specimens for the Predication of High-Grade Cervical Intraepithelial Neoplasia].

The Value of P16 INK4a Cytology for Early Diagnosis of Cervical Cancer

Detection And Pathological Value Of Papillomavirus Dna And P16ink4a And P53 Protein Expression In Cervical Intraepithelial Neoplasia

P16ink4a and Ki-67 Measurement Predict Progression of Cervical Low-Grade Squamous Intraepithelial Lesion.

HPV L1 and P16 Expression in CIN1 to Predict Future CIN2+

[Clinical Value of P16ink4a Immunocytochemistry in Cervical Cancer Screening].

The value of p16ink4a expression by fluorescence in situ hybridization in triage for high risk HPV positive in cervical cancer screening.

Analysis of Factors Affecting the Prognosis of Patients with Cervical Intraepithelial Neoplasia 2

P16INK4A As a Surrogate Biomarker for Human Papillomavirus-Associated Oropharyngeal Carcinoma: Consideration of Some Aspects.

Evaluating the Performance of p16<SUP>INK4a</SUP> Immunocytochemistry in Cervical Cancer Screening

P16ink4a Flow Cytometry of Exfoliated Cervical Cells: Its Role in Quantitative Pathology and Clinical Diagnosis of Squamous Intraepithelial Lesions.

Predictive Significance Of The Alterations Of P16ink4a, P14arf, P53, And Proliferating Cell Nuclear Antigen Expression In The Progression Of Cervical Cancer

p16INK4A and p14ARF expression pattern by immunohistochemistry in human papillomavirus-related cervical neoplasia

Human papillomavirus DNA, HPV L1 capsid protein and p16INK4a protein as markers to predict cervical lesion progression

Increased Ki-67 proliferative index and absence of P16INK4 in CIN-HPV related pathogenic pathways different from cervical squamous intraepithelial lesion

p16<sup>INK4a</sup>and laminin-5γ2 chain expression during the progression of cervical neoplasia

Expressions of EGFR and P16ink4a in CIN Lesions and Their Relations with High-risk Human Papilloma Virus

Evaluation of P16ink4a Immunocytology and Human Papillomavirus (HPV) Genotyping Triage after Primary HPV Cervical Cancer Screening on Self-Samples in China

Prevalence of High-Risk Human Papillomavirus and Cervical Lesion Risk Factors: A Population-Based Study in Zhejiang, China 2010-2019